AMAR - Amarillo Biosciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Amarillo Biosciences, Inc.

4134 Business Park Drive
Amarillo, TX 79110
United States

Full Time Employees2

Key Executives

NameTitlePayExercisedYear Born
Dr. Stephen T. ChenChairman, CEO, Pres, CFO & COO349.63kN/A1950
Mr. Bernard CohenVP of Admin.83.4kN/A1953
Mr. John Junyong Lee Esq.Corp. Legal CounselN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Amarillo Biosciences, Inc., a healthcare company, discovers and develops biologics for the treatment of human and animal diseases. The company owns or licenses six issued patents related to the low-dose oral delivery of interferon; and one patent associated with a dietary supplement, Maxisal. It focuses on research for the treatment of human disease indications primarily influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha. Amarillo Biosciences, Inc. was founded in 1984 and is based in Amarillo, Texas.

Corporate Governance

Amarillo Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.